We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer

This study has suspended participant recruitment.
(the DSMB stopped the trial due to unacceptable side effects in the experimental arm which has not yet been verified)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01088620
First Posted: March 17, 2010
Last Update Posted: March 14, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH
Information provided by (Responsible Party):
WiSP Wissenschaftlicher Service Pharma GmbH
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: January 2014
  Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):